Avicena Group, Inc. (OTCBB: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Drs. Steven Hersch and Diana Rosas presented results regarding the Company’s novel Huntington’s disease treatment candidate HD-02 at the 2007 World Congress on Huntington’s Disease in Dresden, Germany. Drs. Hersch and Rosas, of […]